When was Nouscom founded?

Nouscom was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Nouscom located?

Nouscom is headquartered in Basel, Switzerland.

Who is the current CEO of Nouscom?

Marina Udier Blagovic of Nouscom.

How many employees does Nouscom have?

As of Aug 31, 2026, the latest employee count at Nouscom is 61.

Is Nouscom a funded company?

Nouscom is a funded company, having raised a total of $152M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 17, 2016.

When was the latest funding round of Nouscom?

Nouscom's latest funding was a $***** Series C round on Mar 21, 2024, with participation from 11 investors. Its primary sector is Immunotherapy. In Switzerland, the Immunotherapy sector has seen $30M in funding in 2026 to date.

Where does Nouscom rank among its competitors?

Nouscom ranks 192nd amongst 2487 active competitors, of which 845 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Nouscom?

Nouscom's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Nouscom - 2026 Company Profile, Team, Funding & Competitors

Nouscom is a series C company based in Basel (Switzerland), founded in 2015 by Riccardo Cortese and Cinzia Traboni. It operates as a Developer of viral-vector-based vaccines for the treatment of cancer. Nouscom has raised $152M in funding from investors like Abingworth, Bpifrance and M Ventures. The company has 2487 active competitors, including 845 funded and 618 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of viral-vector-based vaccines for the treatment of cancer. It has product candidates which include Endovax, an antigen-less vaccine, is based on oncolytic viruses capable of infecting and replicating only in cancer cells and causing immunogenic cell death, thereby recruiting T cells at the tumor site and reactivating T cells exhausted in the tumor micro-environment. Exovax is a personalized patient-specific vaccine, based on viral vectors coding for strings of cancer neo-antigens to induce and expand cancer and patient-specific T cells.

Key Metrics

Founded Year

2015

Location

Basel, Switzerland

Stage

Series C

Total Funding

$152M in 4 rounds

Latest Funding Round

Series C, Mar 21, 2024, $*****

Investors

Abingworth & 13 more

Ranked

192^nd among 2487 active competitors

Employee Count

61 as on Aug 31, 2026

Similar Companies

Replimune & 115 more

View Nouscom's full profile

Nouscom has raised a total funding of $152M over 4 rounds. Its first funding round was on May 17, 2016. Its latest funding round was a Series C round on Mar 21, 2024 for $*****. 11 investors participated in its latest round. Nouscom has 14 institutional investors.

Here is the list of recent funding rounds of Nouscom:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 21, 2024	4290273	Series C	2282975	1221464	7028585	2569729
Nov 14, 2023	1918256	Series C	6879066	9640882	8227928	Revelation Partners & 7 more
Nov 06, 2017	1057946	Series B	3956229	1573062	Abingworth	5AM Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Nouscom's funding rounds and investors

The founders of Nouscom are Riccardo Cortese and Cinzia Traboni. Marina Udier Blagovic is the CEO of Nouscom.

Here are the details of Nouscom's key team members:

Riccardo Cortese: Former Co-Founder of Nouscom and founder of 2 other companies, ReiThera and Okairos.
Cinzia Traboni: Former Co-Founder of Nouscom.
Marina Udier Blagovic: CEO of Nouscom.

View details of Nouscom's Founder profiles and Board Members

Nouscom's employee count trend

Nouscom has 61 employees as of Aug 26. Here is Nouscom's employee count trend over the years:

Uncover Nouscom's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nouscom include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Nouscom, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
192nd	Nouscom 2015, Basel (Switzerland), Series C	Developer of viral-vector-based vaccines for the treatment of cancer	$152M	Versant Ventures, Life Sciences Partners ... & 12 others	58/100